Enanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hepatitis C Virus1
Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation
We take a close look at the fund options.
We take a closer look at India, Taiwan, and Malaysia.
The Bond King's departure had a small impact on CEF performance compared with the onslaught in the commodities market.
Appears to be priced in, for now.
Despite the market's wild ride, most CEFs closed the year with positive share price and NAV returns.
A look at ownership data can provide a more detailed look at what mutual funds and institutional players are buying and selling.
When it comes to expenses, CEFs are quite different than open-end mutual funds.